Intradermal Granulocyte–Macrophage Colony-Stimulating Factor Alters Cutaneous Antigen-Presenting Cells and Differentially Affects Local versus Distant Immunization in Humans
| Autor: | Kevin D. Cooper, Gary E. Quinby, Inger B. Kremer, Jennifer W. Gould, Seth R. Stevens, Joanne DiCarlo |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Adult
Cyclopropanes Male Injections Intradermal Immunology Antigen presentation Antigen-Presenting Cells Cell Count Dermatitis Contact Dermis Dinitrochlorobenzene Humans Immunology and Allergy Medicine CD40 Antigens Antigen-presenting cell Skin CD40 integumentary system biology business.industry CD68 Macrophages Granulocyte-Macrophage Colony-Stimulating Factor Dendritic Cells HLA-DR Antigens Dendritic cell Intercellular Adhesion Molecule-1 medicine.anatomical_structure Granulocyte macrophage colony-stimulating factor Delayed hypersensitivity Langerhans Cells Irritants biology.protein Female Immunization business Biomarkers medicine.drug |
| Zdroj: | Clinical Immunology. 96:29-37 |
| ISSN: | 1521-6616 |
| DOI: | 10.1006/clim.2000.4876 |
| Popis: | We hypothesized that intradermal delivery of granulocyte-macrophage colony-stimulating factor (GM-CSF) would alter the number and differentiation state of local antigen-presenting cells and thereby alter immunization strength at that site in humans. GM-CSF or placebo was administered intradermally on consecutive days prior to contact sensitization at that site. In GM-CSF-treated skin, epidermal CD1a(+)S100(+) Langerhans cells were reduced in number and had altered morphology, while the number of dermal CD1a(+), HLA-DR(+), and S100(+) cells was increased. In the deep dermis CD68(+) macrophages were increased. Expression of the APC activation markers CD40 and ICAM-1 was also increased in the dermis. Subjects were sensitized to DNCB through GM-CSF- or placebo-pretreated skin and to DPCP through untreated skin. Subjects immunized through GM-CSF-treated sites exhibited 64% greater elicitation responses to DNCB than placebo-treated subjects. GM-CSF-treated subjects also showed 43% lower responses to DPCP than placebo-treated subjects. The difference between DNCB (local) and DPCP (distant) responses was significantly greater for GM-CSF-treated subjects than for placebo responses (n = 8, P < 0.05). Therefore, local immunization site pretreatment with intradermal GM-CSF enhances immunization efficiency at that site. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect